Fezolinetant - Astellas Pharma
Alternative Names: A2693; AS3472693-00; ESN-364; VEOZA; VEOZAHLatest Information Update: 05 Mar 2024
At a glance
- Originator Euroscreen
- Developer Astellas Pharma
- Class Antineoplastics; Fluorinated hydrocarbons; Ketones; Pyrazines; Small molecules; Thiadiazoles; Triazoles
- Mechanism of Action Neurokinin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Vasomotor symptoms
- Phase II Polycystic ovary syndrome; Uterine leiomyoma
- Discontinued Benign prostatic hyperplasia; Endometriosis; Weight gain
Most Recent Events
- 03 Mar 2024 Astellas Pharma initiates enrolment in a phase III Starlight 3 trial for Vasomotor symptoms in Japan (NCT06206421)
- 03 Mar 2024 Phase-III clinical trials in Vasomotor symptoms in Japan (PO) before February 2024 (Astellas Pharma pipeline, February 2024) (NCT06206408)
- 19 Jan 2024 Astellas Pharma plans a phase III trial in Vasomotor symptoms (In adults) [PO,Tablet] in February 2024 (NCT06206408)